Boston Scientific Corporation (BSX) compounding analysis
Full-size annual and quarterly year-over-year growth charts for revenue, EPS, operating cash flow, EBITDA, and free cash flow against the 15%, 20%, and 30% bars over 3-, 5-, and 10-year windows, with each metric's valuation multiple vs its own history.
Revenue · 10YDoes not currently clear the 15%+, 20%+, or 30%+ revenue bars over 10Y.
- Score
- 22/100
- 10Y CAGR
- 10.4%
- Median YoY
- 10.3%
- YoY volatility
- σ 10.7pp· uneven
- Quarters ≥ 20%
- 5 of 40
- Negative quarters
- 3
- Valuation vs own 10Y history
- P/S 3.7x · 10Y median 5.4x · 5th percentile · as of Aug 19, 2026
How this score is computed
- Quarters at or above 20%: 5 of 40 → 5 of 40 pts
- Steadiness (typical swing 10.7pp) → 17.4 of 25 pts
- Pace (median 10.3% YoY) → 0 of 20 pts
- Latest quarter (7.5% YoY) → 0 of 15 pts
- Score: 22 of 100
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
Across metrics · 10Y
| Metric | 10Y CAGR | Median YoY | YoY σ | Qtrs ≥ 20% | Neg. qtrs |
|---|---|---|---|---|---|
| RevenueRevenue | 10.4% | 10.3% | 10.7pp | 5 of 40 | 3 |
| EPSEPS | — | 35.1% | 530.6pp | 17 of 31 | 8 |
| Op cash flowOperating cash flow | 22.4% | 23.6% | 639.2pp | 16 of 31 | 10 |
| EBITDAEBITDA | 13.1% | 11.6% | 47.4pp | 11 of 37 | 7 |
| FCFFree cash flow | 26.3% | — | — | — | — |
Reported figures over 10Y: annual-series CAGR, median and standard deviation (σ, percentage points) of quarterly year-over-year growth, quarters at or above 20%, and quarters with negative YoY. “—” means the window needs more comparable data.
Scores, qualification bars, and the 0–100 consistency methodology are documented on the compounders list page →
See also: BSX on the compounders surface · All compounders, ranked